Aluminum Salts As an Adjuvant for Pre-pandemic Influenza Vaccines: a Meta-analysis

Overview

Journal Sci Rep

Specialty Science

Date 2018 Aug 1

PMID 30061656

Citations 11

Authors

Yu-Ju Lin

Yun-Jui Shih

Chang-Hsun Chen

Chi-Tai Fang

Affiliations

Soon will be listed here.

Abstract

Avian-origin H5/H7 influenza has the potential to cause the next influenza pandemic. Availability of effective vaccines is an essential part of pre-pandemic preparedness. However, avian influenza surface antigens are poorly immunogenic to humans, which necessitates the use of adjuvants to augment the immunogenicity of pre-pandemic influenza vaccines. Aluminum salts are approved, safe, and affordable adjuvants, but their adjuvanticity for influenza vaccines remains unverified. We conducted the first meta-analysis on this issue. A total of nine randomized controlled trials (2006-2013, 22 comparisons, 2,467 participants in total) compared aluminum-adjuvanted H5N1 vaccines versus non-adjuvanted counterparts. The weighted estimate for the ratio of the seroprotection rate after a single dose of H5N1 vaccine is 0.66 (95% CI: 0.53 to 0.83) by hemagglutination-inhibition assay or 0.56 (95% CI: 0.42 to 0.74) by neutralizing titer assay. The weighted estimate for the risk ratio of pain/tenderness at injection sites is 1.85 (95% CI: 1.56 to 2.19). The quality of evidence is low to very low for seroprotection (due to indirectness and potential reporting bias) and moderate for pain/tenderness (due to potential reporting bias), respectively. The significantly lower seroprotection rate after aluminum-adjuvanted H5N1 vaccines and the significantly higher risk of pain at injection sites indicate that aluminum salts decrease immunogenicity but increase local reactogenicity of pre-pandemic H5N1 vaccines in humans.

Citing Articles

Enhancing antibody levels and T cell activity of quadrivalent influenza vaccine by combining it with CpG HP021.

Ji J, Chen L, Wu Z, Tang T, Zhu L, Zhu M Sci Rep. 2024; 14(1):31424.

PMID: 39733119 PMC: 11682164. DOI: 10.1038/s41598-024-83026-x.

Concentrations, Number of Doses, and Formulations of Aluminium Adjuvants in Vaccines: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Clinical Trials.

Barbateskovic M, Klingenberg S, Krauss S, Kong D, Wu Z, Petersen S Vaccines (Basel). 2023; 11(12).

PMID: 38140168 PMC: 10871092. DOI: 10.3390/vaccines11121763.

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine.

Yong X, Liu J, Zeng Y, Nie J, Cui X, Wang T Hum Vaccin Immunother. 2023; 19(3):2267869.

PMID: 37854013 PMC: 10588526. DOI: 10.1080/21645515.2023.2267869.

Dose-sparing effect of two adjuvant formulations with a pandemic influenza A/H7N9 vaccine: A randomized, double-blind, placebo-controlled, phase 1 clinical trial.

Vanni T, Thome B, Sparrow E, Friede M, Fox C, Beckmann A PLoS One. 2022; 17(10):e0274943.

PMID: 36256646 PMC: 9578608. DOI: 10.1371/journal.pone.0274943.

Aluminium adjuvants versus placebo or no intervention in vaccine randomised clinical trials: a systematic review with meta-analysis and Trial Sequential Analysis.

Krauss S, Barbateskovic M, Klingenberg S, Djurisic S, Petersen S, Kenfelt M BMJ Open. 2022; 12(6):e058795.

PMID: 35738649 PMC: 9226993. DOI: 10.1136/bmjopen-2021-058795.

References

Margine I, Krammer F . Animal models for influenza viruses: implications for universal vaccine development. Pathogens. 2014; 3(4):845-74. PMC: 4282889. DOI: 10.3390/pathogens3040845. View

Mak I, Evaniew N, Ghert M . Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res. 2014; 6(2):114-8. PMC: 3902221. View

Kool M, Fierens K, Lambrecht B . Alum adjuvant: some of the tricks of the oldest adjuvant. J Med Microbiol. 2011; 61(Pt 7):927-934. DOI: 10.1099/jmm.0.038943-0. View

Keitel W, Dekker C, Mink C, Campbell J, Edwards K, Patel S . Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults. Vaccine. 2009; 27(47):6642-8. PMC: 3022490. DOI: 10.1016/j.vaccine.2009.03.015. View

Nolan T, Richmond P, Skeljo M, Pearce G, Hartel G, Formica N . Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine. 2008; 26(33):4160-7. DOI: 10.1016/j.vaccine.2008.05.077. View

Manzoli L, Salanti G, De Vito C, Boccia A, Ioannidis J, Villari P . Immunogenicity and adverse events of avian influenza A H5N1 vaccine in healthy adults: multiple-treatments meta-analysis. Lancet Infect Dis. 2009; 9(8):482-92. DOI: 10.1016/S1473-3099(09)70153-7. View

Gerdts V, van Drunen Littel-van den Hurk S, Griebel P, Babiuk L . Use of animal models in the development of human vaccines. Future Microbiol. 2007; 2(6):667-75. DOI: 10.2217/17460913.2.6.667. View

Chichester J, Mark Jones R, Green B, Stow M, Miao F, Moonsammy G . Safety and immunogenicity of a plant-produced recombinant hemagglutinin-based influenza vaccine (HAI-05) derived from A/Indonesia/05/2005 (H5N1) influenza virus: a phase 1 randomized, double-blind, placebo-controlled, dose-escalation study in.... Viruses. 2012; 4(11):3227-44. PMC: 3509691. DOI: 10.3390/v4113227. View

Ninomiya A, Imai M, Tashiro M, Odagiri T . Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine. 2007; 25(18):3554-60. DOI: 10.1016/j.vaccine.2007.01.083. View

10.

Brady R, Treanor J, Atmar R, Keitel W, Edelman R, Chen W . Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine. 2009; 27(37):5091-5. PMC: 2730950. DOI: 10.1016/j.vaccine.2009.06.057. View

11.

Atmar R, Keitel W . Adjuvants for pandemic influenza vaccines. Curr Top Microbiol Immunol. 2009; 333:323-44. DOI: 10.1007/978-3-540-92165-3_16. View

12.

Kile J, Ren R, Liu L, Greene C, Roguski K, Iuliano A . Update: Increase in Human Infections with Novel Asian Lineage Avian Influenza A(H7N9) Viruses During the Fifth Epidemic - China, October 1, 2016-August 7, 2017. MMWR Morb Mortal Wkly Rep. 2017; 66(35):928-932. PMC: 5689040. DOI: 10.15585/mmwr.mm6635a2. View

13.

De Gregorio E, Tritto E, Rappuoli R . Alum adjuvanticity: unraveling a century old mystery. Eur J Immunol. 2008; 38(8):2068-71. DOI: 10.1002/eji.200838648. View

14.

Yam K, Gupta J, Allen E, Burt K, Beaulieu E, Mallett C . Comparison of AS03 and Alum on immune responses elicited by A/H3N2 split influenza vaccine in young, mature and aged BALB/c mice. Vaccine. 2016; 34(12):1444-51. DOI: 10.1016/j.vaccine.2016.02.012. View

15.

Keitel W, Campbell J, Treanor J, Walter E, Patel S, He F . Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis. 2008; 198(9):1309-16. PMC: 3044935. DOI: 10.1086/592172. View

16.

Ehrlich H, Muller M, Oh H, Tambyah P, Joukhadar C, Montomoli E . A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med. 2008; 358(24):2573-84. DOI: 10.1056/NEJMoa073121. View

17.

Ou H, Yao H, Yao W, Wu N, Wu X, Han C . Analysis of the immunogenicity and bioactivities of a split influenza A/H7N9 vaccine mixed with MF59 adjuvant in BALB/c mice. Vaccine. 2016; 34(20):2362-70. DOI: 10.1016/j.vaccine.2016.03.037. View

18.

Treanor J, Wilkinson B, Masseoud F, Battaglia R, OBrien D, Wolff M . Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine. 2001; 19(13-14):1732-7. DOI: 10.1016/s0264-410x(00)00395-9. View

19.

Layton R, Gigliotti A, Armijo P, Myers L, Knight J, Donart N . Enhanced immunogenicity, mortality protection, and reduced viral brain invasion by alum adjuvant with an H5N1 split-virion vaccine in the ferret. PLoS One. 2011; 6(6):e20641. PMC: 3110201. DOI: 10.1371/journal.pone.0020641. View

20.

MacLeod M, David A, Jin N, Noges L, Wang J, Kappler J . Influenza nucleoprotein delivered with aluminium salts protects mice from an influenza A virus that expresses an altered nucleoprotein sequence. PLoS One. 2013; 8(4):e61775. PMC: 3629017. DOI: 10.1371/journal.pone.0061775. View